GlycoMark (1,5-AG): What Your Number Changes About Your Treatment

The direct answer

GlycoMark measures 1,5-AG, not glucose itself. Because glucose and 1,5-AG compete for reabsorption in the kidney, blood 1,5-AG drops when glucose has been spiking above the renal threshold in the recent past, while HbA1c only reports an average over months and cannot tell a steady mild elevation apart from a swinging pattern with the same average. A low 1,5-AG in a patient whose HbA1c looks acceptable is the scenario where the two tests disagree and where postprandial-focused treatment changes are usually discussed. The test's practical value is limited to patients who are not on an SGLT2 inhibitor, do not have advanced chronic kidney disease, and are not pregnant, because each of those conditions changes 1,5-AG independent of glucose control.

What the test is measuring, in plain terms

1,5-AG is a naturally occurring sugar that the body absorbs from food and normally reabsorbs almost completely in the kidney. When blood glucose rises high enough, it saturates the same transporter the kidney uses to reclaim 1,5-AG, so 1,5-AG spills into urine and blood levels fall. This mechanism has been described in the diabetes literature for decades and is the basis for using 1,5-AG as an indirect marker of recent hyperglycemic excursions, distinct from average glucose.

HbA1c reflects glycation of hemoglobin over roughly the red blood cell lifespan, commonly summarized as a 2 to 3 month weighted average. A patient with stable glucose around 160 mg/dL and a patient whose glucose swings between 80 and 280 mg/dL can land on a similar HbA1c despite very different day-to-day experiences. Guideline bodies, including the American Diabetes Association's Standards of Care, discuss glycemic variability and postprandial glucose as considerations beyond HbA1c, and note that supplemental tools such as continuous glucose monitoring capture information HbA1c cannot (ADA Standards of Care, current supplement; confirm the exact wording in the year's active edition, since Standards of Care are republished annually and language changes).

Where the source studies for this page need verification

Several specific numbers commonly repeated in consumer material about GlycoMark, including precise mg/dL reductions from individual GLP-1 receptor agonist trials, an exact percentage reduction from a meal-sequencing study, and a direct quotation attributed to a named laboratory medicine expert, could not be confirmed against a verified primary source for this draft. Rather than repeat those figures, this article states the direction of each effect and flags that a clinician or medical reviewer should confirm exact magnitudes against the original trial publications before the numbers are used in patient-facing material. A wrong or unverifiable number is a worse outcome than a qualitative statement.

Why HbA1c and 1,5-AG can disagree

Because 1,5-AG responds to spikes rather than averages, two patients with identical HbA1c values can have very different 1,5-AG results if one has smoother glucose control and the other has frequent post-meal excursions above the renal threshold. Published work on 1,5-AG in type 2 diabetes has reported meaningful spread in 1,5-AG among patients grouped by similar HbA1c, supporting the general claim that the two tests are not interchangeable, though the exact magnitude of that spread should be confirmed against the original cohort study rather than assumed from secondary summaries.

Glycemic variability itself, separate from mean glucose, has been linked to oxidative stress markers in patients with type 2 diabetes in prior research. This is a plausible mechanistic reason clinicians care about spikes and not just averages, but it is an association from observational and small mechanistic studies, not proof that lowering 1,5-AG changes hard outcomes like cardiovascular events. That distinction matters: 1,5-AG is a process marker, not an outcome marker.

A decision framework: what a 1,5-AG result should and should not trigger

This framework is meant to help a reader understand what their clinician is likely weighing, not to replace that conversation or to support self-adjustment of medication.

1,5-AG in the higher part of the reference range, HbA1c at goal. Both markers point the same direction. This combination generally does not prompt a treatment change; it is reassurance that fasting and postprandial control both look reasonable.

1,5-AG low, HbA1c at goal. This is the disagreement scenario the test is designed to catch. It suggests recent glucose spikes that HbA1c is not reflecting. It is reasonable to ask your clinician whether a mealtime-focused change makes sense, such as a rapid-acting insulin adjustment, an alpha-glucosidase inhibitor, or a GLP-1 receptor agonist, rather than assuming the current regimen is fully adequate. It is not a signal to change medication on your own.

1,5-AG very low, HbA1c well above goal. At this point 1,5-AG has lost most of its discriminating value, because glucose is exceeding the renal threshold so often that 1,5-AG stays depleted regardless of the pattern of spikes. HbA1c and fasting glucose, not 1,5-AG, should drive escalation decisions here.

1,5-AG stays low after a mealtime-focused medication change. If a clinician re-checks 1,5-AG some weeks after a change intended to reduce spikes and it has not moved, that is a signal the change did not work as intended, and prompts a conversation about dose, timing, or switching agents, not a reason to abandon monitoring.

1,5-AG on an SGLT2 inhibitor, in pregnancy, or with significant chronic kidney disease. The result should generally not be used to judge glycemic control in these situations at all. Ask which alternative marker (CGM data, fructosamine, or standard glucose logs) your clinician is using instead.

Why SGLT2 inhibitors make GlycoMark uninterpretable

SGLT2 inhibitors (for example empagliflozin, dapagliflozin, canagliflozin) work by blocking the same renal transporter that normally reabsorbs both glucose and 1,5-AG. Blocking that transporter causes 1,5-AG to spill into urine regardless of how well glucose is actually controlled. This is a mechanistic certainty, not a subtle statistical caveat: a patient on an SGLT2 inhibitor can have excellent glucose control and still show a very low 1,5-AG. If you are taking one of these medications, or a combination pill that contains one, tell whoever is ordering the test, since the result cannot be interpreted the normal way.

Other situations that change 1,5-AG independent of glucose

• Chronic kidney disease. Reduced kidney filtration lowers 1,5-AG through reduced tubular reabsorption capacity, separate from glucose control. This effect becomes more relevant as kidney function declines, and results in advanced CKD should be interpreted cautiously or avoided.
• Pregnancy. Renal handling of glucose changes in pregnancy in ways that can lower 1,5-AG independent of glycemic control, which limits its usefulness for gestational diabetes monitoring; standard fasting and postprandial glucose testing remains the primary tool in pregnancy.
• Advanced liver disease and malabsorption. Because 1,5-AG levels depend partly on dietary intake and normal absorption, significant liver disease or malabsorption (including after some bariatric procedures) can lower baseline 1,5-AG for reasons unrelated to glucose.

What actually moves the number

There is no supplement or drug that raises 1,5-AG directly. The number only moves when postprandial glucose control improves, because the underlying mechanism is glucose competing with 1,5-AG for renal reabsorption. Strategies discussed in diabetes nutrition and pharmacology literature that plausibly reduce postprandial spikes include:

• Spreading carbohydrate intake across more, smaller meals rather than one or two large ones
• Eating protein and non-starchy vegetables before carbohydrate-heavy foods within the same meal
• Timing rapid-acting insulin to be taken before eating rather than with or after the meal, as directed by your prescriber
• Walking for a short period after meals rather than remaining seated
• Medications specifically aimed at postprandial glucose, including alpha-glucosidase inhibitors, GLP-1 receptor agonists, and rapid-acting insulin, used under clinician guidance

Any medication change belongs to a prescriber conversation. This article does not provide individualized dosing guidance.

Evidence boundary: what is established, plausible, and unproven

Established: 1,5-AG blood levels fall when glucose repeatedly exceeds the renal reabsorption threshold, and this mechanism is distinct from what HbA1c measures. The GlycoMark assay has FDA 510(k) clearance as a laboratory test (verify current label details directly with FDA before relying on specifics). SGLT2 inhibitors lower 1,5-AG independent of glycemic control through a shared transporter mechanism.

Plausible but not proven by this evidence base: That routinely adding 1,5-AG monitoring to standard HbA1c-based care changes hard clinical outcomes such as cardiovascular events, hospitalization, or long-term complication rates. Most published support for 1,5-AG is correlational, showing that it tracks postprandial excursions and glycemic variability, not that acting on it changes outcomes better than standard postprandial monitoring alternatives.

Not established from the material reviewed here: Specific numeric magnitudes for how much particular drugs move 1,5-AG, and exact reference-range cutoffs, without checking the current manufacturer package insert. Treat any precise number you see repeated online, including in this draft's earlier public version, as something to confirm rather than quote.

When this test is not the right tool

GlycoMark is not a diagnostic test for diabetes and does not replace fasting glucose, oral glucose tolerance testing, or HbA1c for diagnosis. It has no role in evaluating acute hyperglycemia, diabetic ketoacidosis, or hypoglycemia; symptoms such as confusion, persistent vomiting, rapid breathing, or altered consciousness require urgent evaluation regardless of any 1,5-AG result. It is also not useful, as discussed above, in patients on SGLT2 inhibitors, with advanced CKD, or during pregnancy.